# Lifelong n-3 PUFA Consumption Reduces HER2+ Mammary Tumour Growth and Alters Immune Markers Compared to Safflower- or Corn Oil-Based Sources of n-6 PUFA

**Authors:** Rahbika Ashraf, Connor D. C. Buchanan, Lyn M. Hillyer, Elizaveta Ogloblina, Geoffrey A. Wood, Richard P. Bazinet, Sanjeena Subedi, A. Michelle Edwards, Young-In Kim, William J. Muller, Jennifer M. Monk, Lindsay E. Robinson, David W. L. Ma

PMC · DOI: 10.3390/nu18040606 · Nutrients · 2026-02-12

## TL;DR

Eating foods rich in n-3 PUFA, like fish oils, can slow breast tumor growth and change immune markers compared to diets high in n-6 PUFA like corn or safflower oil.

## Contribution

This study shows that lifelong n-3 PUFA consumption reduces HER2+ tumor growth and alters immune markers in a mouse model compared to n-6 PUFA sources.

## Key findings

- Mice on n-3 PUFA diets had slower tumor growth compared to those on n-6 PUFA diets.
- n-3 PUFA diets downregulated pro-tumourigenic immune markers like CD206 and F4/80.
- Corn oil's high LA content may promote earlier puberty and tumor growth.

## Abstract

Background: n-3 PUFA derived from marine sources, including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), exhibit potential for breast cancer prevention. In contrast, higher dietary intakes of n-6 PUFA, such as linoleic acid (LA), have been implicated in promoting mammary tumourigenesis. However, there is a need for further exploration into how n-3 PUFA influence breast cancer development in comparison to different amounts and sources of LA. Objective: The purpose of this study was to compare the effects of n-3 PUFA-enriched diets versus n-6 PUFA diets differing in LA content, including corn oil (50% LA) and safflower oil (70% LA), on mammary tumour development in a HER2+ breast cancer model. Methods: Using the HER2+ breast cancer MMTV-neu(ndl)YD5 transgenic mouse model, this study determined the effects of: (1) 10% w/w corn oil (CO, n-6 PUFA, n = 14), (2) 10% w/w safflower oil (SO, n-6 PUFA, n = 14), (3) 3% w/w menhaden oil + 7% w/w CO (3% FO 7% CO, n-3 PUFA, n = 12), and (4) 3% w/w menhaden oil + 7% w/w SO (3% FO 7% SO, n-3 PUFA, n = 14) on puberty onset, tumour incidence, tumour volume, and tumour number in utero until 20 weeks of age. Results: Mice fed the n-3 PUFA-enriched diets showed a lower trajectory of tumour development compared to the n-6 PUFA diets, although the differences for palpated tumour volume and number over time reached significance only between the 10% CO and 3% FO 7% CO groups. This suggests that high LA content in CO may represent a threshold for promoting tumour growth whereby further LA content marginally influences additional tumour development. Exposure to the CO n-6 PUFA diet further resulted in earlier onset of puberty compared to the n-3 PUFA-enriched diet containing CO. To investigate the underlying mechanisms, a qPCR analysis of mammary glands and tumour tissue revealed that the n-3 PUFA diets downregulated the expression of pro-tumourigenic immune markers, including CD206 and F4/80 in the mammary glands and the cannabinoid receptor CB2 in tumours, compared to the n-6 PUFA diets. Conclusions: These findings indicate that the presence of dietary n-3 PUFA plays a key role in modulating mammary tumour development, which may be further influenced by the underlying n-6 PUFA background. The associated changes in immune markers suggest that n-3 PUFA exert anticancer effects in part by shifting the tumour immune microenvironment toward an anti-tumour phenotype and modulating cannabinoid receptor signalling. Collectively, this work informs future human studies investigating the role of dietary fat composition in breast cancer risk.

## Linked entities

- **Proteins:** MRC1 (mannose receptor C-type 1), Adgre1 (adhesion G protein-coupled receptor E1), CNR2 (cannabinoid receptor 2)
- **Chemicals:** eicosapentaenoic acid (PubChem CID 5282847), docosahexaenoic acid (PubChem CID 445580), linoleic acid (PubChem CID 5280450)
- **Diseases:** breast cancer (MONDO:0004989)

## Full-text entities

- **Genes:** Akt1 (Akt serine/threonine kinase 1) [NCBI Gene 11651] {aka Akt, LTR-akt, PKB, PKB/Akt, PKBalpha, Rac}, Cnr2 (cannabinoid receptor 2) [NCBI Gene 12802] {aka CB-2, CB2, CB2-R}, Mrc1 (mannose receptor, C type 1) [NCBI Gene 17533] {aka CD206, MR}, Tbx2 (T-box 2) [NCBI Gene 21385], Eef2 (eukaryotic translation elongation factor 2) [NCBI Gene 13629] {aka Ef-2}, Fads2 (fatty acid desaturase 2) [NCBI Gene 56473] {aka 2900042M13Rik, Fads2a, Fadsd2}, Pik3r1 (phosphoinositide-3-kinase regulatory subunit 1) [NCBI Gene 18708] {aka PI3K, p50alpha, p55alpha, p85alpha}, Egr3 (early growth response 3) [NCBI Gene 13655] {aka EGR-3, Pilot}, Jam3 (junction adhesion molecule 3) [NCBI Gene 83964] {aka 1110002N23Rik, JAM-3, JAM-C, Jcam3}, Adgre1 (adhesion G protein-coupled receptor E1) [NCBI Gene 13733] {aka DD7A5-7, EGF-TM7, Emr1, F4/80, Gpf480, Ly71}, Cd86 (CD86 antigen) [NCBI Gene 12524] {aka B7, B7-2, B7.2, B70, CLS1, Cd28l2}, Nr4a1 (nuclear receptor subfamily 4, group A, member 1) [NCBI Gene 15370] {aka GFRP1, Gfrp, Hbr-1, Hbr1, Hmr, N10}, Bax (BCL2-associated X protein) [NCBI Gene 12028], Zbp1 (Z-DNA binding protein 1) [NCBI Gene 58203] {aka 2010010H03Rik, Dai, Dlm1, mZaDLM}, Cnr1 (cannabinoid receptor 1) [NCBI Gene 12801] {aka CB-R, CB1, CB1A, CB1B, CB1R}, Erbb2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 13866] {aka Erbb-2, HER-2, HER2, Neu, c-erbB2, c-neu}, Id4 (inhibitor of DNA binding 4) [NCBI Gene 15904] {aka Idb4, bHLHb27}, Arg1 (arginase, liver) [NCBI Gene 11846] {aka AI, Arg-1, PGIF}
- **Diseases:** weight gain (MESH:D015430), Mammary Glands and Tumours (MESH:D015674), Breast cancer (MESH:D001943), negative (MESH:D064726), carcinogenesis (MESH:D063646), sarcoma (MESH:D012509), inflammation (MESH:D007249), injury to (MESH:D014947), metastasis (MESH:D009362), mammary tumourigenesis (MESH:D005348), Tumour (MESH:D009369), weight loss (MESH:D015431)
- **Chemicals:** Phospholipid (MESH:D010743), water (MESH:D014867), EPA (MESH:D015118), 7,12-dimethylbenz(a)anthracene (MESH:D015127), linseed oil (MESH:D008043), oxylipins (MESH:D054883), SYBR  Green (MESH:C098022), CO2 (MESH:D002245), 18:3n-3 (MESH:D017962), Lipids (MESH:D008055), arachidonic acid (MESH:D016718), chloroform (MESH:D002725), palmitic acid (MESH:D019308), DHA (MESH:D004281), Endocannabinoid (MESH:D063388), thromboxanes (MESH:D013931), evening primrose oil (MESH:C028498), reactive oxygen species (MESH:D017382), SO (MESH:D012450), Fatty (-), 22:5n-3 (MESH:C026219), SM (MESH:D013109), PE (MESH:C483858), PA (MESH:D011478), LA (MESH:D019787), methanol (MESH:D000432), phosphate (MESH:D010710), PI (MESH:D010716), PUFA (MESH:D005231), menhaden oil (MESH:C033266), boron trifluoride (MESH:C021274), CO (MESH:D003314), n-3 PUFA (MESH:D015525), leukotrienes (MESH:D015289), CO (MESH:D002248), prostaglandins (MESH:D011453), ALA (MESH:D000409), PC (MESH:D010713), Fatty Acid (MESH:D005227), Oil (MESH:D009821), PS (MESH:D010718), MUFA (MESH:D005229)
- **Species:** Carthamus tinctorius (safflower, species) [taxon 4222], Mouse mammary tumor virus (no rank) [taxon 11757], Glycine max (soybean, species) [taxon 3847], Rattus norvegicus (brown rat, species) [taxon 10116], Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** D04092704R
- **Cell lines:** MMTV-neu — Rattus norvegicus (Rat), Transformed cell line (CVCL_AZ70), YD5 — Homo sapiens (Human), Buccal mucosa squamous cell carcinoma, Cancer cell line (CVCL_L080), S2 — Drosophila melanogaster (Fruit fly), Spontaneously immortalized cell line (CVCL_Z232), MMTV — Mus musculus (Mouse), Malignant neoplasms of the mouse mammary gland, Cancer cell line (CVCL_1923)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12943025/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12943025/full.md

## References

86 references — full list in the complete paper: https://tomesphere.com/paper/PMC12943025/full.md

---
Source: https://tomesphere.com/paper/PMC12943025